MELBOURNE, Australia, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (“Telix”, the “Company”) is pleased to announce that Mr. Kevin McCann AM and Dr. Mark Nelson have been appointed to the Board of Telix Pharmaceuticals Limited as Non-Executive Directors. Mr. McCann will also serve in the capacity of Chairman.
Telix Co-Founder and CEO Christian Behrenbruch stated, “We are very pleased to have Kevin and Mark join the Telix board at this important time in the Company’s development. They bring a tremendous amount of experience and perspective in capital markets, corporate governance and commercial strategy.”
Founding Directors Mr. Michael Cawley (Taylor Collison Limited) and Dr. Richard Zimmermann (Chrysalium Consulting) will concurrently step down from their role as Non-Executive Directors. Dr. Zimmermann remains an adviser to the Company.
Mr. Kevin McCann AM : Biography
AM BA LLB (Hons) LLM (Harvard) Life Fellow AICD
Mr Kevin McCann is Chairman of Citadel Group Limited, Dixon Hospitality Limited and the Sydney Harbour Federation Trust. He is a member of the Male Champions of Change, a Pro Chancellor and Fellow of the Senate of the University of Sydney, Co-Vice Chair of the New Colombo Plan Reference Group, a Director of the US Studies Centre, Director and member of the Advisory Board of Evans and Partners and Chair of the National Library of Australia Foundation. Kevin is a former Chairman of Macquarie Group Limited and Macquarie Bank Limited, Origin Energy Limited, Healthscope Limited and ING Management Limited. Kevin practiced as a Commercial Lawyer as a Partner of Allens Arthur Robinson from 1970 to 2004 and was Chairman of Partners from 1995 to 2004.
Kevin has a Bachelor of Arts and Law (Honours) from Sydney University and a Master of Law from Harvard University. He was made a Member of the Order of Australia for services to the Law, Business and the Community in 2005 and is a Life Fellow of the Australian Institute of Company Directors.
Dr. Mark Nelson : Biography
B.Sc (Hons) (Melb), M.Phil (Cantab), Ph.D (Melb)
Dr Mark Nelson is Chairman and Co-Founder of the Caledonia Investments Group, and a Director of The Caledonia Foundation. He is Vice President of the Board of Trustees of the Art Gallery of New South Wales, Deputy Chairman of Art Exhibitions Australia, a Director of Kaldor Public Art Projects and serves as a Governor of the Florey Neurosciences Institute. Previously Mark was a Director of The Howard Florey Institute of Experimental Physiology and Medicine, and served on the Commercialisation Committee of the Florey Institute. Mark was educated at the University of Melbourne and University of Cambridge (UK).
About Telix Pharmaceuticals Limited
Telix is an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR). The Company is developing an advanced portfolio of oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is an unlisted public company.
For more information visit www.telixpharma.com.
Investor Relations Contact Kyahn Williamson Head of Investor Communication WE Buchan @: kwilliamson@buchanwe.com.au
